# Evaluation of the impact of a nurse-led telephone follow-up on treatment compliance of patients treated from a locally advanced or metastatic non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation(s).The PARTAGE study.

**First published:** 24/03/2016

**Last updated:** 16/10/2026

Study Finalised

## Administrative details

**EU PAS number**

EUPAS12954

**Study ID**

12955

**DARWIN EU® study**

No

**Study countries**

France

**Study description**

Evaluation of the impact of nurse-led telephone on treatment compliance

**Study status**

Finalised

# Research institutions and networks

## Institutions

### Hôpital Européen Georges Pompidou

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

## Contact details

**Study institution contact**

Florian SCOTTE florian.scotte@yahoo.fr

**Study contact**

florian.scotte@yahoo.fr

**Primary lead investigator**

Florian SCOTTE

Primary lead investigator

## Study timelines

**Date when funding contract was signed**
Planned: 18/12/2015

Actual: 18/12/2015

**Study start date**
Planned: 15/10/2015

Actual: 18/12/2015

**Data analysis start date**
Planned: 18/06/2018

**Date of final study report**
Planned: 18/03/2019

Actual: 23/04/2018

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Boehringer

## Study protocol

1200-0227_CTP_English_version_final-rule_Redacted.pdf (1.26 MB)

## Regulatory

**Was the study required by a regulatory body?**

No

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Other study registration identification numbers and links

1200.227

NCT02483416

# Methodological aspects

## Study type

## Study type list

**Study type:**

Non-interventional study

**Scope of the study:**

Drug utilisation

Evaluation of patient-reported outcomes

Healthcare resource utilisation

Safety study (incl. comparative)

**Data collection methods:**

Primary data collection

---

**Study design:**

Routine clinical practice, randomised, multicentre study.

**Main study objective:**

To evaluate, during routine clinical practice, the impact of nurse-led telephone follow-up on overall patient treatment compliance with oral targeted therapy (cumulated dose* during the 3-month follow-up).

## Study drug and medical condition

**Medical condition to be studied**

EGFR gene mutation

Lung cancer metastatic

## Population studied

**Short description of the study population**

Patients enrolled in the study were male or female adult outpatients ≥18years), diagnosed with stage IIIb/IV NSCLC locally advanced or metastatic, with activating mutation(s) of EGFR and EGFR-Tyrosine Kinase Inhibitors (TKI) naïve, for whom a decision of treatment with afatinib monotherapy had been taken in the frame of its marketing
authorization.

---

**Age groups**

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

---

**Estimated number of subjects**

500

## Study design details

**Setting**

14 French active centres

---

**Outcomes**

The impact of nurse-led telephone follow-up on overall patient treatment compliance, Patient and health care professional 's satisfactionary, quality of life

---

**Data analysis plan**

At the inclusion visit (D0), the investigator will ask the patient whether he would like to participate in the study and will obtain his written consent. Patients agreeing to participate will be randomised (3:1 ratio) and included in one of the following 2 groups:Group without `remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team (100 patients).Group with `remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team (300 patients).All the patients will be seen according to normal practice by the study medical team.Patients in the group with `remote additional personalised nurse-led follow-up will be

contacted 8 times during the s

## Documents

**Abstract of study report**

1200-0227_Synopsis.pdf (213.43 KB)

# Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

**Data sources (types)**

Administrative healthcare records (e.g., claims)

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

**Check completeness**

Unknown

**Check stability**

Unknown

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No